27 April 2026
27 April 2026
Following the transaction’s completion, Sun Pharma will have a combined revenue of $12.4bn.
Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.
With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British biotech’s future.
Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.
The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.
Results provide evidence needed to challenge the step-through reimbursement requirements that have restricted Qulipta's uptake in Europe.
The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s first domestically produced anti-CD38 immunotherapy for multiple myeloma (MM).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
